Twenty Visits, Twelve Without a Single Production Line
A GMP cleanroom contractor launched a new-customer drive in the Yangtze River Delta this year. The sales team compiled a list of more than two hundred entities in the industry, booked appointments, and visited twenty of them. The debrief revealed that only eight actually had cleanroom renovation needs: five were drug distribution companies that sold and resold without any manufacturing floor; three held drug approval numbers but had contracted all production out to other factories — shell entities under the MAH system; and four listed "APIs" in their business scope but were in practice intermediary commodity traders.
Twenty visits, at a fully-loaded cost of RMB 25,000 per sales-person-month, meant those twelve fruitless calls had burned half a month of headcount — before counting travel.
The root cause is simple: China's pharmaceutical licensing system is easy for outsiders to confuse. A drug manufacturing license (药品生产许可证), a drug distribution license (药品经营许可证), and a drug registration approval (药品注册批件) differ by just one character in their names, yet the purchasing power and production requirements of the entities that hold them are worlds apart. For upstream suppliers selling GMP cleanroom systems, pharmaceutical equipment, or pharma excipients, the ability to distinguish real manufacturers from a license list before the first cold call is the most critical prerequisite for new-customer development.
What These Factories Look Like
Licensing Is the First Dimension — the Three Certificates Cannot Be Confused
Pharmaceutical industry entities fall broadly into two categories: manufacturers and distributors. Both display words like "pharma," "bioscience," or "medical" in their public records, yet they represent completely different businesses.
A drug manufacturing license (药品生产许可证) is the first hard threshold for answering the question "Is this a real pharmaceutical manufacturer?" License holders must pass a GMP conformance inspection and operate compliant production buildings, cleanrooms, and quality management systems. No drug manufacturing license means no lawful manufacturing capability — full stop.
A drug distribution license (药品经营许可证) covers the pharmaceutical supply chain. Its holders are wholesalers, pharmacy chains, and medical distribution agents. Their business is buying and reselling drugs; they have almost no need to purchase GMP cleanroom systems.
Drug approval numbers / marketing authorizations (the MAH system) introduce a newer layer of complexity: since 2019 China's Marketing Authorization Holder system allows the license holder to contract production to a third-party factory — meaning an entity can hold a drug approval number without owning a single square meter of production space.
The genuine procurement entity is a company that holds a drug manufacturing license and operates actual production lines — not a distributor with a distribution license, and not an MAH holder that delegates manufacturing to another factory.
Industrial Clusters: APIs in Shandong, Finished-Dose Forms in the Yangtze Delta and Guangdong
Pharmaceutical factories cluster geographically in recognizable patterns. Shandong and Shijiazhuang are the two main hubs for chemical APIs: Binzhou, Weifang, and Tai'an in Shandong host large API industrial parks, while Shijiazhuang is associated with antibiotic APIs. The Yangtze River Delta (Taizhou, Lianyungang, Suzhou) is home to a dense concentration of finished-dose and biopharmaceutical companies; Taizhou's "China Pharmaceutical City" is a national-level base, and Lianyungang's Hengrui cluster anchors a surrounding supply chain. Guangzhou has a mature, long-established finished-dose manufacturing community. Beijing leans toward R&D; factories with meaningful production lines there are comparatively few.
Real Pharma Factory vs. Drug Trader / CSO — Two Checkpoints: License and Shop Floor
Trading entities in the pharmaceutical industry fall into roughly three types: pure drug distributors (holding only a distribution license), contract sales organizations (CSOs, focused on drug promotion with no production credentials), and shell MAH holders (holding an approval number but no production line). All three may have the word "pharma" or "medical" in their business-scope registration, making them indistinguishable from corporate registry data alone.
Real manufacturing factories have two hard requirements:
First, they hold a drug manufacturing license, which specifies both the scope and the address of production. This can be verified directly on the National Medical Products Administration (NMPA) website; the production scope will explicitly state categories such as "chemical pharmaceutical preparations," "APIs," or "biologics."
Second, they operate GMP-compliant cleanrooms and production facilities. A genuinely running pharma factory will have tablet presses, filling lines, reactors, freeze-drying machines, and other process equipment, along with cleanrooms scaled to match production volume. Distributors and CSOs have none of these.
Three Steps to Finding Pharmaceutical Factory Customers
Step 1 — Lock Down Your Target Factory Type by Product Line and Pharma Process Segment
The pharmaceutical supply chain is long, and the right target factory type varies significantly by upstream product. Start with a precise definition on the product side:
- GMP cleanroom systems / HVAC for controlled environments: the core targets are factories building new or renovating existing GMP production suites — priority on sterile preparations (injectables, lyophilized powder-for-injection), biologics, and inhalation products, which require the highest cleanliness classes; cleanroom project values for these facilities range from several million to tens of millions of RMB
- Pharmaceutical equipment (tablet presses, filling lines, freeze-dryers, reactors): match equipment type to factory type — chemical preparations, injectables, or API synthesis; freeze-dryer demand concentrates among biologics and lyophilized-powder producers
- Purified water / water-for-injection systems: nearly all finished-dose factories are targets — one of the broadest coverage categories
- Filtration and chromatography media: biopharmaceuticals, monoclonal antibodies, and vaccine producers purchase large volumes
- Analytical instruments (HPLC, mass spectrometry, dissolution testers): continuous purchases by QA/QC departments; relevant across finished-dose and API factories
- Packaging materials (vials, aluminum caps, blister foil, ampoules): covers virtually all finished-dose factories — injectables, tablets, capsules
Once the product line is fixed, narrow the geographic focus: for API equipment and cleanroom systems, prioritize Shandong and Shijiazhuang; for finished-dose equipment and biopharmaceutical consumables, prioritize Taizhou, Lianyungang, Suzhou, and Guangzhou. Tianxia Gongchang covers 4.8 million real manufacturing enterprises in China — use region and sub-category filters for the first-pass scoping.
Step 2 — Catch the "Active Procurement" Window Using Regulatory Signals
Large-ticket purchases at pharmaceutical factories are almost always triggered by two types of events: regulatory events (GMP certification or inspection, new product approval) and capacity events (new plant construction, expansion, process upgrades). Identifying these signals early puts you at the very front of the procurement window.
GMP certification / conformance inspections are the most important trigger. Before an inspection, factories systematically overhaul equipment, purification systems, and validation frameworks. Before a new facility applies for GMP certification, cleanroom systems, process equipment, and purified-water systems must all be purchased and validated. This window is the highest-priority intervention point for GMP cleanroom contractors.
New product approvals leading to production-line builds. The NMPA publishes weekly lists of approved drug reviews. Once a new product is approved, the factory typically needs to complete production-line construction or renovation within six to twelve months — procurement activity surges in a concentrated window.
Bioequivalence (BE) studies for generic drug approvals continue to drive upgrades. Bioequivalence requirements for oral solid dosage forms require factories to re-pass BE trials; some need to upgrade tablet presses, add dissolution testers, and renovate cleanrooms. Large numbers of products remain in the evaluation pipeline each year.
QA/QC/process-engineer hiring. These three job functions are exclusive markers of real pharmaceutical manufacturers — distribution companies and CSOs have no logical reason to post QA or QC roles. Multiple concurrent postings for these positions frequently signal capacity expansion or a new production-line launch.
Capacity-expansion announcements and facility news. Large-scale pharma expansions typically require environmental-impact assessments, which become public filings; local drug regulatory authorities publish notices when drug manufacturing licenses are issued or amended; and relocating into Taizhou Pharmaceutical City, Lianyungang Xuwei Pharma Park, or similar clusters almost always coincides with new GMP facility construction.
Step 3 — Use Tianxia Gongchang to Confirm Real Manufacturers and Export a Usable List
Steps 1 and 2 narrow scope and timing. Step 3 filters distributors, CSOs, and MAH shells out of the candidate list, leaving only companies with genuine production lines.
Open Tianxia Gongchang, select "pharmaceutical manufacturing" or "biopharmaceuticals" as the industry category, layer on the relevant industrial clusters (Shandong / Shijiazhuang / Taizhou / Lianyungang / Suzhou / Guangzhou), and set a size range. The key action: Tianxia Gongchang has applied factory-identification logic across its 4.8 million real manufacturing enterprises in China, tagging which entities are genuine production facilities and which are traders — enabling direct filtering of drug distributors with no production lines. Given how heavily the pharmaceutical industry mixes trading entities into its rosters, this step typically reduces a list by one-third to one-half.
Once the list is confirmed, prioritize using the Step 2 regulatory signals: factories that hold a drug manufacturing license and have had recent GMP activity or a new product approval go to tier one; large API factories with a track record of continuous expansion go to tier two; smaller finished-dose manufacturers are evaluated against your product line before deciding whether to include them in a nurture pipeline.
How to Use Tianxia Gongchang in the Pharmaceutical Sector
Factory-Identification Baseline — Untangling the License Maze Before You Start
Tianxia Gongchang covers 4.8 million real manufacturing enterprises in China and applies factory-attribute verification to separate entities that have physical plants, production lines, and genuine manufacturing capability from traders and distributors. The pharmaceutical industry needs this capability more urgently than most: general corporate-registry platforms can surface companies with the word "drug" in their business scope, but cannot distinguish a drug manufacturing license from a distribution license. Tianxia Gongchang moves the question of "does this entity actually manufacture?" to the very beginning of the workflow, letting upstream sales teams start on solid ground rather than spending the first round of calls manually verifying a mixed-entity list.
Pharmaceutical-Specific Filtering Workflow
When running pharmaceutical industry filters inside Tianxia Gongchang, apply conditions in this sequence:
- Industry category: chemical pharmaceutical preparations manufacturing, chemical API manufacturing, biologics manufacturing (choose one or combine, depending on your product line)
- Industrial cluster / region: Shandong (APIs), Shijiazhuang (APIs), Taizhou / Lianyungang / Suzhou (finished-dose and biopharma), Guangzhou (finished-dose) — select according to your sales coverage territory
- Size range: focus on mid-tier factories with stable GMP certification and annual revenue above RMB 10 million; these factories run cleanrooms on a sustained basis and purchase equipment and consumables continuously
- Factory-attribute filter: show only records identified as genuine production entities, directly removing distributors and trading companies
- Export the list, then re-rank using drug manufacturing license category, recent GMP inspection activity, and hiring signals
Tianxia Gongchang integrates all of these filter layers in a single interface, eliminating the need to cross-reference the NMPA website, job-posting platforms, and environmental-impact announcement portals by hand — and outputs a pharmaceutical factory list that is ready for visit scheduling.
Reference Sheets You Can Use Immediately
Industry Screening Keywords
| Dimension | Keywords / Parameters |
|---|---|
| Industry sub-segment | Chemical pharmaceutical preparations, chemical APIs, biologics, traditional Chinese medicine preparations, generics, innovative drugs, APIs |
| Regulatory signals | Drug manufacturing license, pharmaceutical GMP, GMP conformance inspection, drug approval number, MAH, Drug Master File (DMF) registration, bioequivalence approval |
| Process keywords | Sterile preparations, lyophilized powder-for-injection, injectables, tablet press, filling line, freeze-dryer, reactor, cleanroom, purified-water system |
| Industrial cluster locations | Shandong (Binzhou / Weifang / Tai'an), Shijiazhuang, Taizhou (China Pharmaceutical City), Lianyungang, Suzhou, Guangzhou |
Demand-Signal Dictionary
| Signal Type | Trigger Words / Events | What It Means |
|---|---|---|
| GMP certification / inspection | GMP conformance inspection, GMP certification, preparing for NMPA inspection, facility remediation | Concentrated procurement window for cleanroom systems, purification equipment, and process equipment |
| New product approval | Drug approval number granted, new drug marketing authorization, bioequivalence study passed | Production-line build or expansion procurement kick-off |
| Capacity expansion | New GMP facility construction, move into industrial park, new plant-site activation, expansion announcement | Large-scale procurement of cleanroom systems, pharma equipment, and purified-water systems |
| Hiring signals | Recruiting QA engineer / QC engineer / process engineer / cleanroom operator / validation engineer | Marker of a real production factory in expansion mode; distributors and CSOs do not post these roles |
| Bioequivalence studies | Generic drug bioequivalence evaluation, BE trial, dissolution study | Tablet-press upgrades and analytical-instrument procurement |
Recommended Excel Follow-Up Columns
Factory Name | Primary Dosage Form / Product | Drug Manufacturing License No. | Industrial Cluster / City | GMP Status (Under Inspection / Remediation / New Certification) | Recent Activity (New Approval / Expansion / BE Study) | First Contact Date | Pipeline Stage | Notes
Four Questions to Verify a Real Pharmaceutical Manufacturer
- Can the company provide its drug manufacturing license number (verifiable on the NMPA website, which shows the production scope and address)?
- Does the company operate its own cleanroom, and what GMP category covers it (sterile preparations / APIs / traditional Chinese medicine, etc.)?
- Does the company have an internal QA department with dedicated QA/QC engineer positions (distribution companies and CSOs have no such function)?
- Is the holder of the drug approval number the same legal entity as the manufacturer (to rule out pure MAH holders that delegate all production to a third party)?
The License List Is the Door — Once Inside, Look at the Shop Floor
The pharmaceutical industry is one of the few where "is this entity legally permitted to manufacture?" is codified in law and queryable in a public database. Drug manufacturing licenses, GMP conformance declarations, drug registration approvals — any upstream sales professional can verify these directly on the NMPA website at no cost.
The hard part is what comes after: production scale, procurement needs, and cleanroom renovation plans are scattered across job postings, capacity announcements, and certification timelines, and still have to be assembled piece by piece. What Tianxia Gongchang does is systematize factory-attribute identification — filtering, from 4.8 million real manufacturing enterprises in China, the pharmaceutical manufacturers that hold drug manufacturing licenses and operate genuine production facilities, and delivering a list to GMP cleanroom contractors and pharmaceutical equipment sales teams that starts clean, with the noise already removed.
Picking customers from a license list means picking the entities that genuinely need cleanrooms, genuinely purchase pharmaceutical equipment, and genuinely have ongoing consumable demand. The gap between those entities and the ones that don't determines how many effective sales visits a team can actually complete in a month.